Week 96 efficacy of lopinavir/ritonavir monotherapy in virologically suppressed patients with HIV: a randomized non-inferiority trial (ANRS 140 DREAM)

Jean-Luc Meynard; Laetitia Moinot; Roland Landman; Laurence Morand-Joubert; Amel Besseghir; Sami Kolta; Bruno Spire; Eve Todesco; Olivier Bouchaud; Catherine Fagard; Geneviève Chene; Pierre-Marie Girard

doi:10.1093/jac/dky055

Journal articles

Week 96 efficacy of lopinavir/ritonavir monotherapy in virologically suppressed patients with HIV: a randomized non-inferiority trial (ANRS 140 DREAM)

Jean-Luc Meynard ^{1, *} Laetitia Moinot ² Roland Landman ^{3, 4} Laurence Morand-Joubert ^{1, 5} Amel Besseghir ² Sami Kolta ^{6, 7} Bruno Spire ^{8, 9, *} Eve Todesco ⁵ Olivier Bouchaud ¹⁰ Catherine Fagard ² Geneviève Chene ^{2, 11} Pierre-Marie Girard ^{1, 5}

* Corresponding author

1 Service des maladies infectieuses et tropicales [CHU Saint-Antoine]

2 BPH - Bordeaux population health

3 IMEA - Institut de médecine et d'épidémiologie appliquée [AP-HP Hôpital Bichat-Claude Bernard]

4 IAME (UMR_S_1137 / U1137) - Infection, Anti-microbiens, Modélisation, Evolution

5 iPLESP - Institut Pierre Louis d'Epidémiologie et de Santé Publique

6 CRESS (U1153 / UMR_A_1125 / UMR_S_1153) - Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité

7 Service de rhumatologie [CHU Cochin]

8 SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD - Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale

9 ORS PACA - Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille]

10 Service des maladies infectieuses et tropicales

11 Pôle de Santé Publique - Service d’information Médicale [CHU de Bordeaux]

Abstract : Background: Sparing of antiretroviral drug classes could reduce the toxicity and cost of maintenance treatment for HIV infection. Objectives: To evaluate the non-inferiority of efficacy and the safety of lopinavir/ritonavir (r) monotherapy versus a single-tablet regimen of efavirenz, emtricitabine and tenofovir (EFV/FTC/TDF) over 2 years. Methods: Adults on stable ART with plasma HIV-1 RNA viral load <50 copies/mL for the past 12 months and no documented treatment failure were randomized to receive either lopinavir/r or EFV/FTC/TDF for 2 years. The primary endpoint was the proportion of patients without treatment failure at week 96 (viral load <50 copies/mL at week 96, confirmed at week 98), without study treatment discontinuation, a new AIDS-defining illness, or death. Results: In the ITT analysis, the primary endpoint was reached by, respectively, 64% and 71% of patients in the lopinavir/r (n = 98) and EFV/FTC/TDF arms (n = 97), yielding a difference of -6.8% (lower limit of the 95% two-sided CI: -19.9%). Sanger and UltraDeep sequencing showed the occurrence of PI mutations in the lopinavir/r arm (n = 4) and of NNRTI and/or NRTI mutations in the EFV/FTC/TDF arm (n = 2). No unexpected serious clinical events occurred. Conclusions: Lopinavir/r monotherapy cannot be considered non-inferior to EFV/FTC/TDF. PI resistance rarely emerged in the lopinavir/r arm and did not undermine future PI options. Two years of lopinavir/r monotherapy had no deleterious clinical impact when compared with EFV/FTC/TDF.

Document type :

Journal articles

Domain :

Life Sciences [q-bio] / Santé publique et épidémiologie

Complete list of metadata

https://www.hal.inserm.fr/inserm-02096600
Contributor : Christine Dupuis <>
Submitted on : Thursday, April 11, 2019 - 2:20:16 PM
Last modification on : Friday, June 11, 2021 - 8:38:03 AM

Week 96 efficacy of lopinavir/ritonavir monotherapy in virologically suppressed patients with HIV: a randomized non-inferiority trial (ANRS 140 DREAM)

Links full text

Identifiers

Collections

Citation

Export

Metrics

673

Week 96 efficacy of lopinavir/ritonavir monotherapy in virologically suppressed patients with HIV: a randomized non-inferiority trial (ANRS 140 DREAM)

Links full text

Identifiers

Collections

Citation

Export

Share

Metrics

673